HER-2阳性乳腺癌的新辅助治疗现状及展望  

The current and progress of neoadjuvant treatment of HER-2 positive breast cancer

作　　者：张艳秋[1] 王昳凡 王简[1] 殷咏梅[1] 

机构地区：[1]南京医科大学第一附属医院肿瘤科,南京210029

出　　处：《临床肿瘤学杂志》2017年第3期264-271,共8页Chinese Clinical Oncology

摘　　要：人表皮生长因子受体(HER-2)高表达被视为乳腺癌预后不良的重要预测因素,但随着抗HER-2治疗药物研发的进步、新辅助治疗理念的建立及临床经验的积累,其预后已得到改善。新辅助治疗是局部晚期乳腺癌的标准治疗,并被广泛用于可手术的早期患者,以提高保乳率。新辅助治疗与术后辅助治疗同样可以改善患者的无病生存期(DFS)和总生存期(OS)。近年来曲妥珠单抗等抗HER-2靶向药物及治疗方法发展迅速,新辅助治疗为药物的研究和开发提供很好的研究平台,HER-2阳性乳腺癌新辅助治疗相关问题已成为肿瘤学关注的热点问题,本文将对此作一简要综述。Over-expression of human epidermal growth factor receptor 2（HER-2） protein has long been established as a major negative prognostic factor of breast cancer. But the clinical landscape of HER-2 positive breast cancers has literally been transformed by the approval of anti-HER-2 agents, the establishment of neoadjuvant treatment and the accumulation of clinical experience. Neoadjuvant treatment is the standard care of locally advanced breast cancer, and its current role has expanded to the treatment of early breast cancer, increasing the rate of breast-conserving surgery. Most large randomized trials comparing neoadjuvant treatment against identical adjuvant systemic therapy indicate that these strategies offer equivalent disease-free survival（DFS） and overall survival （OS） outcomes. With the development of HER-2 targeted therapy and neoadjuvant treatment as a unique plat form for drug development, neoadjuvant therapy for HER-2 positive breast cancer is being increasingly studied. This review summarizes the recent advances made in the area of neoadjuvant therapy in HER-2 positive breast cancer.

关 键 词：乳腺癌 HER-2阳性 新辅助治疗 

分 类 号：R737.9[医药卫生—肿瘤]